TOKYO — Fujifilm Holdings announced on Tuesday that it has signed a contract worth more than $3 billion to manufacture biologic drugs in the U.S. for a major American pharmaceutical company.
The 10-year deal with Regeneron Pharmaceuticals, which marks the largest publicly known manufacturing contract for biopharmaceuticals on record, comes as U.S. pharmaceutical companies are doubling down on domestic supply in response to economic security policies and tariff measures by U.S. President Donald Trump.
